Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

NCT03541902 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Malignant Neoplasms of Urinary Tract
Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
Sarcomatoid Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Unclassified Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib
DRUG: Sunitinib Malate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]